[go: up one dir, main page]

UA94052C2 - Похідні піридазину - Google Patents

Похідні піридазину

Info

Publication number
UA94052C2
UA94052C2 UAA200801149A UAA200801149A UA94052C2 UA 94052 C2 UA94052 C2 UA 94052C2 UA A200801149 A UAA200801149 A UA A200801149A UA A200801149 A UAA200801149 A UA A200801149A UA 94052 C2 UA94052 C2 UA 94052C2
Authority
UA
Ukraine
Prior art keywords
pyridazine derivatives
esters
compounds
formula
pharmaceutically acceptable
Prior art date
Application number
UAA200801149A
Other languages
English (en)
Russian (ru)
Inventor
Курт Амрайн
Даніель Хунцікер
Бернд Кун
Александер В. Майвег
Вернер НАЙДХАРТ
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36781523&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA94052(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of UA94052C2 publication Critical patent/UA94052C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/28—Cinnolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

У заявці описані сполуки формули EMBED ISISServer , (I) а також їх фармацевтично прийнятні солі й складні ефіри, у якій R1-R4 мають значення, вказані в пункті 1 формули винаходу, які можна застосовувати у вигляді фармацевтичних композицій.
UAA200801149A 2005-07-05 2006-06-26 Похідні піридазину UA94052C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05106098 2005-07-05
PCT/EP2006/063533 WO2007003521A2 (en) 2005-07-05 2006-06-26 Pyridazine derivatives as 11beta-hydroxysteroid dehydrogenase type 1 inhibitors

Publications (1)

Publication Number Publication Date
UA94052C2 true UA94052C2 (uk) 2011-04-11

Family

ID=36781523

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200801149A UA94052C2 (uk) 2005-07-05 2006-06-26 Похідні піридазину

Country Status (33)

Country Link
US (1) US7678795B2 (uk)
EP (1) EP1904455B1 (uk)
JP (1) JP4787321B2 (uk)
KR (1) KR100979582B1 (uk)
CN (1) CN101528713B (uk)
AR (1) AR054814A1 (uk)
AT (1) ATE520670T1 (uk)
AU (1) AU2006265201C1 (uk)
BR (1) BRPI0613565A2 (uk)
CA (1) CA2612740C (uk)
CL (1) CL2009001936A1 (uk)
CR (1) CR9587A (uk)
CY (1) CY1112401T1 (uk)
DK (1) DK1904455T3 (uk)
EC (1) ECSP088082A (uk)
ES (1) ES2370039T3 (uk)
HK (1) HK1134087A1 (uk)
HR (1) HRP20110808T1 (uk)
IL (1) IL188182A (uk)
MA (1) MA29909B1 (uk)
MX (1) MX2007016352A (uk)
MY (1) MY144209A (uk)
NO (1) NO20076431L (uk)
NZ (1) NZ564260A (uk)
PL (1) PL1904455T3 (uk)
PT (1) PT1904455E (uk)
RS (1) RS51994B (uk)
RU (1) RU2401832C2 (uk)
SI (1) SI1904455T1 (uk)
TW (1) TWI323258B (uk)
UA (1) UA94052C2 (uk)
WO (1) WO2007003521A2 (uk)
ZA (1) ZA200710972B (uk)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7834178B2 (en) 2006-03-01 2010-11-16 Bristol-Myers Squibb Company Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
MX2009001043A (es) 2006-08-08 2009-02-06 Sanofi Aventis Imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para preparalas, medicamentos que comprenden estos compuestos y su uso.
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009131958A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazine derivatives
WO2009131947A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising pyridazine derivatives
TW201014822A (en) 2008-07-09 2010-04-16 Sanofi Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
US8501940B2 (en) * 2008-07-15 2013-08-06 Hoffmann-La Roche Inc. Tetrahydrocinnoline derivatives
US20100022572A1 (en) 2008-07-18 2010-01-28 Kowa Company, Ltd. Novel spiro compound and medicine comprising the same
WO2010023931A1 (ja) 2008-08-29 2010-03-04 興和株式会社 １－アダマンチルアゼチジン－２－オン誘導体及びこれを含有する医薬
JP5477973B2 (ja) 2008-10-29 2014-04-23 興和株式会社 １，２−ジアゼチジン−３−オン誘導体及びこれを含有する医薬
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US20100267706A1 (en) * 2009-04-20 2010-10-21 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
ES2350077B1 (es) 2009-06-04 2011-11-04 Laboratorios Salvat, S.A. Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1.
BR112012003973A2 (pt) 2009-08-26 2015-09-08 Sanofi Sa hidratos de fluoroglicosídeo heteroaromático cristalinos, produtos farmacêuticos compreendendo estes compostos e seu uso
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012154967A1 (en) 2011-05-12 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2015067575A1 (en) * 2013-11-05 2015-05-14 F. Hoffmann-La Roche Ag 5,6,7,8-tetrahydro-5,8-methanocinnoline derivatives as rorc modulators for the treatment of autoimmune diseases
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
CA3042317A1 (en) * 2016-11-01 2018-05-11 F.Hoffmann-La Roche Ag Pyridazine derivatives as rorc modulators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2474214A1 (en) * 2002-02-05 2003-08-14 Novo Nordisk A/S Novel aryl- and heteroarylpiperazines
TWI314455B (en) * 2002-12-10 2009-09-11 Nippon Kayaku Kk 3-phenyl-cinnoline derivatives and anti-tumor agent containing the same
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
JP2006522747A (ja) * 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ 縮合１，２，４−トリアゾールの薬学的使用

Also Published As

Publication number Publication date
AU2006265201C1 (en) 2010-12-09
HRP20110808T1 (hr) 2011-12-31
KR20080019272A (ko) 2008-03-03
RS51994B (en) 2012-04-30
MY144209A (en) 2011-08-15
NO20076431L (no) 2008-04-01
WO2007003521A2 (en) 2007-01-11
SI1904455T1 (sl) 2011-11-30
JP4787321B2 (ja) 2011-10-05
CR9587A (es) 2008-01-25
TW200738241A (en) 2007-10-16
CY1112401T1 (el) 2015-12-09
ECSP088082A (es) 2008-02-20
HK1134087A1 (en) 2010-04-16
US7678795B2 (en) 2010-03-16
KR100979582B1 (ko) 2010-09-01
CL2009001936A1 (es) 2010-02-19
IL188182A (en) 2011-10-31
ZA200710972B (en) 2008-10-29
CA2612740A1 (en) 2007-01-11
AR054814A1 (es) 2007-07-18
RU2008103483A (ru) 2009-08-10
TWI323258B (en) 2010-04-11
CN101528713B (zh) 2013-05-22
NZ564260A (en) 2010-12-24
AU2006265201A1 (en) 2007-01-11
PL1904455T3 (pl) 2012-01-31
JP2009500370A (ja) 2009-01-08
ES2370039T3 (es) 2011-12-12
CA2612740C (en) 2011-07-26
US20070010519A1 (en) 2007-01-11
IL188182A0 (en) 2008-03-20
ATE520670T1 (de) 2011-09-15
DK1904455T3 (da) 2011-09-12
RU2401832C2 (ru) 2010-10-20
CN101528713A (zh) 2009-09-09
MA29909B1 (fr) 2008-11-03
MX2007016352A (es) 2008-03-05
WO2007003521A3 (en) 2009-02-05
BRPI0613565A2 (pt) 2011-01-18
EP1904455A2 (en) 2008-04-02
AU2006265201B2 (en) 2010-07-15
PT1904455E (pt) 2011-10-04
EP1904455B1 (en) 2011-08-17

Similar Documents

Publication Publication Date Title
UA94052C2 (uk) Похідні піридазину
TW200608972A (en) Aryl-pyridine derivatives
TW200626558A (en) Indazolone derivatives
TW200740764A (en) Pyrazolone derivatives
MX2010005824A (es) Derivados de aminotiazol.
MX2008016426A (es) Derivados de alquilpiridazina como inhibidores de 11 beta hidroxiesteroide deshidrogenasa tipo 1(11b-hsd 1).
IN2012DN03337A (uk)
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
MX2009003939A (es) Derivados de imidazolona e imidazolidinona como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1 para diabetes.
MX2009006598A (es) Derivados de sulfamida como transferasa de carnitina palmitoil del higado (l-cptl).
MX2010005714A (es) Compuestos de piridina.
NO20070445L (no) Pyrimidinderivater.
WO2006077025A3 (en) Morpholines as 5ht2c agonists
MX2009003169A (es) Derivados de sulfonamida.
TW200730511A (en) Chroman compounds
IN2012DN01232A (uk)
TW200730510A (en) Chroman compounds
MY139522A (en) New alkyl-pyridines as 11-beta inhibitors for diabetes
PA8579301A1 (es) Derivados de tiazol
NZ596464A (en) Anticancer compound and pharmaceutical composition containing the same
MX2009013003A (es) Derivados de piperidina-amida.
IN2012DN01234A (uk)
MX2007003105A (es) Derivados de bencimidazol, composiciones que los contienen, sus preparaciones y sus usos i.
MX2009001572A (es) Derivados de arilpiperazina y usos de los mismos.
WO2007145563A8 (en) Benzimidazole derivatives which are to be used as antagonist for the cb1-receptor